Phathom Pharmaceuticals, Inc. - Common Stock (PHAT)

CUSIP: 71722W107

Q2 2024 13F Holders as of 30 Jun 2024

Holder snapshot 7 signals
Share change
+2,735,886
Put/Call ratio
7.5%
SEC-reported price per share
$10.30
Number of holders
113
Value change
+$27,856,700
Number of buys
64
Open additional details 1 more signal available
Number of sells
36
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
79,611,764

Security key

71722W107

Report period

Q2 2024

Institutions

113

Top holders

10

Ownership snapshot

Top reported holders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Medicxi Ventures Manageme...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
0/15
Latest evidence
23 May 2024
13F 3/4/5 Highest disclosed value: $107,360,543 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Frazier Life Sciences Management, L.P. has the largest disclosed position value at $107.36M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Disclosed position value Top 5
Medicxi Ventures Management (Jers... $79.27M
TAKEDA PHARMACEUTICAL CO LTD $33.49M
Frazier Life Sciences Management,... $107.36M
Carlyle Group Inc. $37.1M
Invesco Ltd. $33.56M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Medicxi Ventures Management (Jersey) Ltd
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$79,273,755
7,464,572 shares
— 31 Mar 2024
TAKEDA PHARMACEUTICAL CO LTD
13F 3/4/5
Company · 10%+ Owner
—
denominator unverified
$33,487,165
3,153,217 shares
— 31 Mar 2024
Frazier Life Sciences Management, L.P.
13F
Company
13F
—
denominator unverified
$107,360,543
10,109,279 shares
— 31 Mar 2024
Carlyle Group Inc.
13F
Company
13F
—
denominator unverified
$37,101,133
3,496,808 shares
— 31 Mar 2024
Invesco Ltd.
13F
Company
13F
—
denominator unverified
$33,556,959
3,159,789 shares
— 31 Mar 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$29,155,935
2,745,380 shares
— 31 Mar 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
113
Shares
58,109,780
Rows available
113
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
112
Q2 2024 holders
113
Holder diff
1
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 value Q2 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .